CA-VIZ.AI
8.2.2023 15:16:51 CET | Business Wire | Press release
Viz.ai, the leader in AI-powered disease detection and care coordination, and TeleSpecialists LLC, a physician-owned management service organization committed to providing exceptional emergent and non-emergent neurology and psychiatric patient care via telemedicine, announced new data presented today at the International Stroke Conference (ISC) from the VALIDATE (Validation of Artificial intelligence to LImit Delays in Acute stroke Treatment and Endovascular therapy) study. The study demonstrated that hospital utilization of Viz’ AI-powered care coordination platform was associated with a 39.5 minute reduction in patient arrival to time of first contact with the neurointerventionalist for need for potential emergency endovascular treatment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230208005564/en/
VALIDATE Study: Median Arrival to Neurointerventionalist Notification Times (Graphic: Business Wire)
“In the world of stroke treatment, the saying ‘time is brain’ comes from the fact that when brain tissue is deprived of oxygenated blood, approximately two million neurons die every minute,” said Theresa Sevilis, DO, director of clinical research at TeleSpecialist and study co-author. “VALIDATE data show that use of the Viz platform resulted in a clinically important decrease in the time it took for large blood vessel occlusion recognition and contact with the interventional team, which in turn may translate to fewer neurons dying and, ultimately, better patient outcomes.”
The independent VALIDATE study analyzed data extracted from acute stroke consultations seen by TeleSpecialists’ neurologists in the emergency department across 166 facilities in 17 states. A total of 14,116 patients were included from two groups: those seen in hospitals using AI (n=8,557) and those seen in hospitals not using AI (n=5,559). The study found that the median door to neurointerventionalist notification time for AI was 50 minutes compared to the median door to neurointerventionalist notification time for non-AI at 89.5 minutes (p <0.001), a difference of 39.5 minutes. Importantly, the statistically significant (p<0.01) improvement in time to large clot recognition and contact with the neurointerventional team at Viz-enabled centers occurred regardless of whether the center did or did not have thrombectomy-capability.
"These data, which resulted from measuring the impact of our platform on patient care in the real world, reinforce results we’ve seen in previous studies that have typically involved a single center with a limited number of patients,” said Jayme Strauss, chief clinical officer, Viz.ai. “The first multi-center study involving a large number of patients, VALIDATE compared results from the same time period between hospitals that used the Viz.ai platform and those that did not have AI software, thus eliminating the potential confounding effect of changes in workflow that occur in hospitals over time. This tightly controlled scientific study clearly illustrates the tremendous impact of our technology.”
“The VALIDATE results demonstrate a time improvement in emergency stroke workflow between Viz-enabled and non-Viz-enabled centers that was statistically significant and highly clinically important,” said Thomas Devlin, MD, PhD, Professor of Neurology at the University of Tennessee Health Science Center, and co-author of the study. “The study design allowed for very careful and rigorous insight into exactly how powerful the Viz.ai platform is at expediting treatment for one of the most time-sensitive conditions in all of medicine.”
Viz.ai and TeleSpecialists announced a strategic partnership last year aimed at bringing AI-powered care coordination together with leading telestroke neurologists to optimize time to treatment and improve patient outcomes across the United States.
For more information on the study results, visit the ISC website.
About Viz.ai, Inc.
Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 200 million lives across 1,300+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz Platform is an intelligent care coordination solution that identifies more patients with a particular disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by clinical evidence, the Viz Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.
About TeleSpecialists, LLC
TeleSpecialists is a leading national physician-owned provider of telemedicine solutions for quality-focused hospitals and healthcare systems that sets the standard for rapidly accessible remote neurology and psychiatry services, both emergent and non-emergent.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230208005564/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Darktrace Selects Navan to Modernise Travel Program25.2.2026 10:00:00 CET | Press release
Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Darktrace, a global leader in AI for cybersecurity, to upgrade its global travel program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225522665/en/ Darktrace Selects Navan to Modernise Travel Program “As Darktrace accelerates its expansion, in-person collaboration is critical,” said David Smith, Chief People Officer at Darktrace. “Navan’s inventory and user experience will ensure our teams and customers can easily connect, while we can maintain financial control.” As the UK-based cybersecurity company grows, Darktrace sought a partner to consolidate its travel operations, minimize administrative burden, and improve the booking experience for its workforce. Previously hampered by fragmented processes, Darktrace required a solution that would increase platform adoption and empower its employees to tra
AI: The New Insider Threat Facing Organizations25.2.2026 09:00:00 CET | Press release
Thales 2026 Data Threat Report Finds 70% of Organizations Rank AI as Top Data Security Risk As AI systems gain broader access to enterprise data across environments, organizations must treat data visibility and encryption as core security elements. AI-enabled deepfakes and misinformation are increasing the effectiveness of identity-based attacks. Today, credential theft is the leading attack technique against cloud infrastructure (67%). Nearly 60% of companies report deepfake-driven incidents, and 48% experience damage from AI-generated misinformation Investment in AI security is growing, with 30% of companies allocating dedicated budgets; however, 53% are still relying on existing security budget According to the Thales 2026 Data Threat Report, organizations across various markets including automotive, energy, finance and retail say the rapid pace of AI-driven transformation is now their biggest security challenge. Based on the report’s research, conducted by S&P Global 451 Research,
Zuper and Vonage Reimagine Network Connectivity for Skilled Trades with Quality on Demand25.2.2026 09:00:00 CET | Press release
Zuper to receive early access to Vonage Quality on Demand network API, for high-stakes field workflows - ensuring reliable network performance for live video, wearables, and inspections across industries like HVAC, electrical, general construction, roofing, manufacturing, and more Zuper, the AI operating system for the trades, and Vonage, part of Ericsson, have entered into a Memorandum of Understanding (MoU) to enter into a collaboration to integrate Vonage’s network APIs into the Zuper platform. The collaboration will provide Zuper with early access to Vonage network powered solutions, starting with Quality on Demand (QoD), where mobile network performance can be selectively applied to support critical field workflows, delivering improved latency, reliability, and connected experiences for mobile workforces. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225852261/en/ QoD is the first advanced network API being integrat
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom